

Asia Pacific

Bangkok
Beijing
Hanoi
Ho Chi Minh City
Hong Kong
Jakarta*
Kuala Lumpur*
Manila*
Melbourne
Shanghai
Singapore
Sydney
Taipei
Tokyo

**Europe, Middle East
& Africa**

Abu Dhabi
Almaty
Amsterdam
Antwerp
Bahrain
Baku
Barcelona
Berlin
Brussels
Budapest
Cairo
Casablanca
Doha
Dusseldorf
Frankfurt/Main
Geneva
Istanbul
Johannesburg
Kyiv
London
Luxembourg
Madrid
Milan
Moscow
Munich
Paris
Prague
Riyadh
Rome
St. Petersburg
Stockholm
Vienna
Warsaw
Zurich

Latin America

Bogota
Brasilia*
Buenos Aires
Caracas
Guadalajara
Juarez
Mexico City
Monterrey
Porto Alegre*
Rio de Janeiro*
Santiago
Sao Paulo*
Tijuana
Valencia

North America

Chicago
Dallas
Houston
Miami
New York
Palo Alto
San Francisco
Toronto
Washington, DC

* Associated Firm

BY SEDAR

September 13, 2016

Ontario Securities Commission
British Columbia Securities Commission
Alberta Securities Commission

Re: Titan Medical Inc. (the “Corporation”) – Prospectus Supplement dated September 13, 2016 to the Short Form Base Shelf Prospectus dated August 18, 2015

Dear Sirs/Mesdames:

We refer to the prospectus supplement dated September 13, 2016 to the short form base shelf prospectus dated August 18, 2015 of the Corporation in relation to the offering of units of the Corporation (the “**Prospectus Supplement**”).

We hereby consent to the references to our firm name on the cover page of the Prospectus Supplement and under the heading “Legal Matters” and to the reference to our firm name and to the use of our opinions under the headings “Eligibility for Investment” and “Certain Canadian Federal Income Tax Considerations” in the Prospectus Supplement.

We confirm that we have read the Prospectus Supplement and have no reason to believe that there are any misrepresentations (as defined in the *Securities Act* (Ontario)) in the information contained in the Prospectus Supplement that is derived from our opinions referred to above or that is within our knowledge as a result of the services we performed in connection with such opinions.

This letter is delivered to the addressees pursuant to the requirements of Section 4.2(a)(vii) of National Instrument 44-101.

Yours very truly,

(signed) “*Baker & McKenzie LLP*”

2201406-v2\TORDMS